Skip to main content
Glama

Compare Entities

compare_entities
Read-onlyIdempotent

"Compare X and Y" / "X vs Y" / "X versus Y" / "which is bigger / better / larger / more profitable" / "rank these companies" / "head to head" — side-by-side comparison of 2–5 companies or drugs in ONE parallel call. ALWAYS PREFER over sequential single-pack lookups when comparing entities. type="company" pulls LATEST 10-K revenue + net income + cash + long-term debt from SEC EDGAR/XBRL (off-calendar fiscal years handled correctly — AAPL Sep, NVDA Jan, etc.). type="drug" pulls FAERS adverse-event counts, FDA approval counts, active trial counts. Results sorted by primary metric so "largest" / "most" / "biggest" reads off the top of the response. Returns paired data + pipeworx:// citation URIs per entity. Replaces 8–15 sequential lookups.

Input Schema

TableJSON Schema
NameRequiredDescriptionDefault
typeYesEntity type: "company" or "drug".
valuesYesFor company: 2–5 tickers/CIKs (e.g., ["AAPL","MSFT"]). For drug: 2–5 names (e.g., ["ozempic","mounjaro"]).

TDQS

A4.7/5.0
Behavior5/5

Does the description disclose side effects, auth requirements, rate limits, or destructive behavior?

Annotations already mark the tool as read-only and idempotent, but the description adds critical behavioral details: it pulls latest 10-K financials from SEC EDGAR/XBRL for companies (including off-calendar fiscal year handling) and FAERS/FDA data for drugs. It also describes result sorting and citation URIs, going well beyond annotations.

Agents need to know what a tool does to the world before calling it. Descriptions should go beyond structured annotations to explain consequences.

Conciseness4/5

Is the description appropriately sized, front-loaded, and free of redundancy?

The description is a single dense paragraph, information-rich with no wasted words. It front-loads typical user queries and covers all key aspects. However, it could be slightly more structured (e.g., breaking company vs. drug into separate lines) for easier scanning, but overall it's efficient and concise.

Shorter descriptions cost fewer tokens and are easier for agents to parse. Every sentence should earn its place.

Completeness4/5

Given the tool's complexity, does the description cover enough for an agent to succeed on first attempt?

For a tool with no output schema, the description adequately explains return format (paired data + citation URIs) and sorting order. It covers data sources and entity types thoroughly. Minor gaps include error handling or limitations (e.g., only latest fiscal year), but given the complexity, it's sufficiently complete.

Complex tools with many parameters or behaviors need more documentation. Simple tools need less. This dimension scales expectations accordingly.

Parameters4/5

Does the description clarify parameter syntax, constraints, interactions, or defaults beyond what the schema provides?

Input schema coverage is 100% with descriptions for both parameters. The description adds value by providing concrete examples ('AAPL', 'MSFT' for companies; 'ozempic', 'mounjaro' for drugs) and clarifying the format (tickers/CIKs vs. names) and constraints (2–5 items). This enriches the schema's bare definitions.

Input schemas describe structure but not intent. Descriptions should explain non-obvious parameter relationships and valid value ranges.

Purpose5/5

Does the description clearly state what the tool does and how it differs from similar tools?

The description opens with user-language examples like 'Compare X and Y' and 'head to head', immediately clarifying the tool's purpose: side-by-side comparison of 2–5 companies or drugs. It distinguishes between entity types and specifies the data pulled for each, making the purpose unmistakable and differentiated from single-entity siblings.

Agents choose between tools based on descriptions. A clear purpose with a specific verb and resource helps agents select the right tool.

Usage Guidelines5/5

Does the description explain when to use this tool, when not to, or what alternatives exist?

The description explicitly instructs to 'ALWAYS PREFER over sequential single-pack lookups when comparing entities', providing clear when-to-use guidance. It also implies when not to use (single entity lookups) by contrasting with sequential lookups, and the sibling list confirms alternatives like 'profile' and 'quote' exist.

Agents often have multiple tools that could apply. Explicit usage guidance like "use X instead of Y when Z" prevents misuse.

Try in Browser

Glama MCP Gateway

Add one secure layer between your agents and this server.

TDQS

A3.7/5.0
Disambiguation3/5

While many tools have distinct purposes, there is notable overlap between price, quote, eod, and time_series for price data. Also, the multiple ask_pipeworx variants and deep_research could cause confusion about which to use for factual queries. Some tools like bet_research and polymarket_arbitrage also have overlapping domains.

Naming Consistency4/5

Most tools follow a descriptive snake_case pattern (ai_visibility_check, ask_pipeworx, compare_entities). A few are single words (cryptocurrencies, indices, profile) which is acceptable. No mixing of camelCase or other conventions, so consistent overall.

Tool Count2/5

47 tools is quite high for a single server. While the domain is broad (financial data, prediction markets, SEC filings, etc.), many tools are highly specific (e.g., polymarket_arbitrage, bet_research, scan_dependency) and could be consolidated. The count feels bloated and adds cognitive load.

Completeness4/5

The tool set is impressively comprehensive, covering stocks, forex, crypto, economic data, SEC filings, prediction markets, entity resolution, and even claims validation. Minor gaps exist (e.g., limited drug data despite having some tools), but overall the surface supports a wide range of agentic workflows without obvious missing operations.